InVivo Therapeutics 46188BAC6 Bond
NVIVDelisted Stock | USD 1.38 0.07 5.34% |
InVivo Therapeutics holds a debt-to-equity ratio of 0.088. . InVivo Therapeutics' financial risk is the risk to InVivo Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
InVivo Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. InVivo Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps InVivo Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect InVivo Therapeutics' stakeholders.
For most companies, including InVivo Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for InVivo Therapeutics Holdings, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, InVivo Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
InVivo |
Given the importance of InVivo Therapeutics' capital structure, the first step in the capital decision process is for the management of InVivo Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of InVivo Therapeutics Holdings to issue bonds at a reasonable cost.
Popular Name | InVivo Therapeutics INVH 27 15 JAN 34 |
Equity ISIN Code | US46186M6057 |
Bond Issue ISIN Code | US46188BAC63 |
S&P Rating | Others |
Maturity Date | Others |
Issuance Date | Others |
InVivo Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
INVH 415 15 APR 32 | US46188BAD47 | Details | |
INVH 2 15 AUG 31 | US46188BAA08 | Details | |
INVH 23 15 NOV 28 | US46188BAB80 | Details | |
INVH 27 15 JAN 34 | US46188BAC63 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning InVivo Therapeutics Use of Financial Leverage
Understanding the structure of InVivo Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to InVivo Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.